Sumitomo Mitsui Trust Holdings, Inc. Mirati Therapeutics, Inc. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$162.05 - $240.27 $557,776 - $827,009	-3,442 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$113.26 - $167.27 $240,111 - $354,612	-2,120 Reduced 38.12%	3,442 $572,000
Q2 2020 Jul 27, 2020	BUY	$72.01 - $120.39 $11,521 - $19,262	160 Added 2.96%	5,562 $635,000
Q1 2020 Apr 27, 2020	BUY	$69.78 - $116.21 $376,951 - $627,766	5,402 New	5,402 $415,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.